Physician profile
William Vetter
NPI 1992775480
$1,267.00
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $71.85 · 2022: $168 · 2023: $273 · 2024: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $183.15 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $155.89 | 2019-2024 | |
| Abbvie INC. | $113.93 | 2022-2024 | |
| Pfizer INC. | $112.30 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $102.96 | 2023-2024 | Farxiga, Airsupra |
| Mylan Specialty L.P. | $93.55 | 2019-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.41 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $53.13 | 2020-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $50.80 | 2022-2023 | |
| Glaxosmithkline, LLC. | $44.68 | 2019-2024 | Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $43.38 | 2022-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $39.70 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.10 | 2019-2024 | Jardiance |
| Allergan, INC. | $32.14 | 2019-2020 | |
| Amgen INC. | $29.38 | 2019-2024 | Evenity, Prolia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $19.38 | 2019 | |
| Exact Sciences Corporation | $19.06 | 2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $19.02 | 2023 | Veozah |
| Dexcom, INC. | $18.19 | 2024 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $17.43 | 2024 | Daybue |
| Janssen Pharmaceuticals, INC | $16.16 | 2023 | Spravato |
| Neurocrine Biosciences, INC. | $12.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Vetter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.